General
|
RAC |
Re:
General Comments / Chat
|
|
RaceOncology
|
11K |
4.1M |
28 |
03/07/24 |
03/07/24 |
General
|
11K
|
4.1M
|
28
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
20 |
03/07/24 |
03/07/24 |
ASX - By Stock
|
2.2K
|
779K
|
20
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
RaceOncology
|
11K |
4.1M |
35 |
03/07/24 |
03/07/24 |
General
|
11K
|
4.1M
|
35
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
RaceOncology
|
11K |
4.1M |
58 |
03/07/24 |
03/07/24 |
General
|
11K
|
4.1M
|
58
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
RaceOncology
|
168 |
48K |
118 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
168
|
48K
|
118
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
RaceOncology
|
130 |
39K |
37 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
130
|
39K
|
37
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
RaceOncology
|
80 |
26K |
62 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
26K
|
62
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
RaceOncology
|
80 |
26K |
53 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
26K
|
53
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
RaceOncology
|
80 |
26K |
100 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
26K
|
100
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
RaceOncology
|
80 |
26K |
75 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
26K
|
75
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
RaceOncology
|
80 |
26K |
142 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
26K
|
142
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
RaceOncology
|
906 |
275K |
16 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
906
|
275K
|
16
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
RaceOncology
|
22K |
7.9M |
77 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
22K
|
7.9M
|
77
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
RaceOncology
|
2.3K |
795K |
41 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.3K
|
795K
|
41
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
21 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
21
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
11 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
11
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
21 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
21
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
16 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
16
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
46K |
80 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
146
|
46K
|
80
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
26 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
50 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
50
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
53 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
53
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
81 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
81
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
46 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
46
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
42 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
42
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
49 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
49
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
779K |
99 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
2.2K
|
779K
|
99
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
46K |
35 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
146
|
46K
|
35
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
46K |
27 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
146
|
46K
|
27
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
46K |
63 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
146
|
46K
|
63
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
46K |
86 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
146
|
46K
|
86
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
46K |
50 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
146
|
46K
|
50
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
RaceOncology
|
2.3K |
795K |
23 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
2.3K
|
795K
|
23
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
19 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
80
|
26K
|
19
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
49 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
80
|
26K
|
49
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
67 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
80
|
26K
|
67
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
71 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
80
|
26K
|
71
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
72 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
26K
|
72
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
40 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
26K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
40 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
26K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
68 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
26K
|
68
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
RaceOncology
|
110 |
38K |
10 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
110
|
38K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
RaceOncology
|
80 |
26K |
119 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
26K
|
119
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
RaceOncology
|
110 |
38K |
50 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
110
|
38K
|
50
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
RaceOncology
|
82 |
27K |
61 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
27K
|
61
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
RaceOncology
|
82 |
27K |
43 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
27K
|
43
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
RaceOncology
|
82 |
27K |
39 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
27K
|
39
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
RaceOncology
|
82 |
27K |
59 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
27K
|
59
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
RaceOncology
|
82 |
27K |
23 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
27K
|
23
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
RaceOncology
|
22K |
7.9M |
114 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
22K
|
7.9M
|
114
|
|